Eikon Therapeutics Reports Early PARP1 and WRN Clinical Data at ESMO

The company reported updated Phase 1/2 data for PARP1 inhibitors EIK1003 and EIK1004, and first clinical signals for WRN inhibitor EIK1005, with tolerability and early activity across multiple tumor settings.